XOSL
AKBM
Market cap892mUSD
Jun 18, Last price
99.00NOK
1D
2.06%
1Q
-3.88%
IPO
-1.00%
Name
Aker Biomarine ASA
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Aker BioMarine AS, a subsidiary of Aker ASA, is a Norwegian company established in 2006 and headquartered in Lysaker. The firm is dedicated to the global development, production, and commercialization of ingredients sourced from krill, serving diverse applications in nutraceuticals, dietary supplements, and animal feed. Its market reach extends across Norway, the Americas, Asia Pacific, Europe, the Middle East, and Africa. The company operates through two distinct segments: Ingredients and Brands. Its product portfolio features Superba, a krill-derived nutraceutical ingredient recognized for its phospholipid complex containing choline, omega-3s, and astaxanthin. Other key offerings include QRILL Aqua, designed for aquaculture, and QRILL Pet, tailored for animal feed. Aker BioMarine also provides LYSOVETA, an innovative delivery platform based on LPC-bound EPA and DHA from krill, alongside INVI, a hydrolyzed protein isolate suitable for food and beverage applications. Beyond its core ingredient business, the company distributes natural supplements and various human health and nutrition products. Furthermore, it oversees AION, a circular solutions provider focused on waste recycling and material reuse.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||